This population-based registry was designed to provide robust and updated information on the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of newly diagnosed Philadelphia positive, BCR-ABL1+ CML that occurred in a sample of 92.5 million adults living in 20 European countries, were registered over a median period of 39 months. 94.3% of the 2904 CML patients were diagnosed in chronic phase (CP). Median age was 56 years. 55.5% of patients had comorbidities, mainly cardiovascular (41.9%). High-risk patients were 24.7% by Sokal, 10.8% by EURO, and 11.8% by EUTOS risk scores. The raw incidence increased with age from 0.39/100,000/year in people 20-29 years old to 1.52 in those >70 years old, and showed a maximum of 1.39 in Italy and a minimum of 0.69 in Poland (all countries together: 0.99). The proportion of Sokal and Euro score high-risk patients seen in many countries indicates that trial patients were not a positive selection. Thus from a clinical point of view the results of most trials can be generalized to most countries. The incidences observed among European countries did not differ substantially. The estimated number of new CML cases per year in Europe is about 6370.

3 Medizinische Klinik University of Heidelberg in Mannheim Mannheim Germany

Department of Hematology and Bone Marrow Transplantation Tartu University Hospital Tartu Estonia

Department of Hematology and Oncology L and A University of Bologna Bologna Italy

Department of Hematology and Transplantation Medical University of Gdansk Gdansk Poland

Department of Hematology Jagellonian University Hospital Krakow Poland

Department of Hematology Oncology University Hospital Palacky University Olomouc Czech Republic

Department of Hematology University Clinical Centre Ljubljana Slovenia

Department of Hematology University Hospital Bratislava Slovakia

Department of Hematology VU University Medical Center Amsterdam The Netherlands

Department of Internal Medicine 4 Haematology and Oncology Klinikum Wells Grieskirchen Wells Austria

Department of Internal Medicine Hematooncology Masaryk University Hospital Brno Czech Republic

Department of Internal Medicine University of Uppsala Uppsala Sweden

Department of Medicine Division of Hematology University Hospital Center Zagreb Croatia

Department of Specialistic Diagnostic and Experimental Medicine University of Bologna Bologna Italy

Division of Hematology Azienda Policlinico OVE University of Catania Catania Italy

FSBI Hematology Research Center of Healthcare Ministry of Russian Federation Moscow Russia

Hematology and Research Institute Hospital de la Princesa Madrid Spain

Hematology Research Unit Helsinki University Central Hospital and Hematology Research Unit Biomedicum Helsinki Finland

INSERM CIC 1402 CHU Poitiers France

Institut za Haematologiju Clinical Center of Serbia University of Belgrade Belgrade Serbia

Institute for Medical Information Sciences Biometry and Epidemiology Ludwig Maximilians Universitaet Munich Germany

Institute of Hematology St Petersburg State Medical University St Petersburg Russian Federation

Institute of Translational Medicine Royal Liverpool University Hospital Liverpool UK

Munich Cancer Registry Ludwig Maximilians Universitaet Munich Germany

National Hematology Centre Riga Eastern Clinical University Hospital Riga Latvia

Novartis Oncology Europe Origgio Italy

The Karaiskakio Foundation Nicosia Cyprus

Vilnius University Hospital Santariskiu Klinikos Vilnius Lithuania

Zobrazit více v PubMed

J Natl Compr Canc Netw. 2013 Nov;11(11):1327-40 PubMed

Blood. 2010 Nov 11;116(19):3724-34 PubMed

Blood. 2012 Jul 26;120(4):761-7 PubMed

N Engl J Med. 2010 Jun 17;362(24):2251-9 PubMed

J Clin Oncol. 2012 Oct 1;30(28):3486-92 PubMed

J Natl Cancer Inst. 2011 Apr 6;103(7):553-61 PubMed

Blood. 1984 Apr;63(4):789-99 PubMed

Eur J Cancer. 2011 Nov;47(17):2493-511 PubMed

Blood. 2013 May 30;121(22):4439-42 PubMed

Blood. 2013 Aug 15;122(7):1284-92 PubMed

Nat Rev Drug Discov. 2009 Jun;8(6):447 PubMed

Blood. 2012 Mar 1;119(9):1981-7 PubMed

Blood. 2011 Dec 22;118(26):6760-8 PubMed

J Clin Oncol. 2010 Jan 20;28(3):424-30 PubMed

Blood. 2013 Jun 13;121(24):4867-74 PubMed

Cancer. 2012 Jun 15;118(12):3123-7 PubMed

Leukemia. 2013 Oct;27(10):2016-22 PubMed

Blood. 2011 Jul 21;118(3):686-92 PubMed

Leukemia. 2009 Mar;23(3):602-4 PubMed

J Clin Oncol. 2011 Jun 20;29(18):2514-20 PubMed

Haematologica. 2006 Oct;91(10):1400-4 PubMed

Blood. 2013 Aug 8;122(6):872-84 PubMed

J Clin Oncol. 2011 Apr 20;29(12):1634-42 PubMed

J Natl Cancer Inst. 1998 Jun 3;90(11):850-8 PubMed

Haematologica. 2011 Jan;96(1):55-61 PubMed

N Engl J Med. 2010 Jun 17;362(24):2260-70 PubMed

J Clin Oncol. 2008 Jul 10;26(20):3358-63 PubMed

Haematologica. 2013 Aug;98(8):e95-7 PubMed

N Engl J Med. 2003 Mar 13;348(11):994-1004 PubMed

N Engl J Med. 2010 Dec 23;363(26):2511-21 PubMed

J Clin Oncol. 2010 Jun 1;28(16):2748-54 PubMed

Hematol Oncol. 1997 Nov;15(4):173-89 PubMed

Lancet. 2007 Jul 28;370(9584):342-50 PubMed

Blood. 2011 May 26;117(21):5591-9 PubMed

Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents